Nanosphere (NASDAQ: NSPH) is one of 79 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it compare to its peers? We will compare Nanosphere to related businesses based on the strength of its risk, institutional ownership, profitability, analyst recommendations, dividends, earnings and valuation.
Institutional and Insider Ownership
50.8% of shares of all “Advanced Medical Equipment & Technology” companies are held by institutional investors. 18.8% of shares of all “Advanced Medical Equipment & Technology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Nanosphere and its peers revenue, earnings per share and valuation.
Nanosphere’s peers have higher revenue and earnings than Nanosphere. Nanosphere is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
This table compares Nanosphere and its peers’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
This is a breakdown of recent ratings for Nanosphere and its peers, as provided by MarketBeat.
||Strong Buy Ratings
As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 3.78%. Given Nanosphere’s peers higher possible upside, analysts clearly believe Nanosphere has less favorable growth aspects than its peers.
Nanosphere peers beat Nanosphere on 6 of the 8 factors compared.
Nanosphere Company Profile
Nanosphere, Inc. is engaged in developing, manufacturing and marketing an advanced molecular diagnostics platform, the Verigene System, which enables genomic and protein testing on a single platform. The Verigene System includes a molecular diagnostics workstation that is a single use consumable for testing. The Verigene System consists of a microfluidics processor, a touchscreen reader and disposable test cartridges. The Company is focused on the infectious disease diagnostics market. Its Infectious Disease Assays include Respiratory Virus with Sub-Typing (RV+); Respiratory Pathogens/Expanded Panel (RP Flex); Bloodstream Infection (BSI) Panels, which include Blood Culture – Gram Positive (BC-GP), Blood Culture – Gram Negative (BC-GN) and Blood Culture – Yeast (BC-Y); C. difficile (CDF), and Enteric Panel (EP). Its Human Pharmacogenetic Assays include Hypercoagulation (FV, FII, MTHFR Panel) and CYP2C19 Genetic Variance. It is focused on the infectious disease diagnostics market.
Receive News & Ratings for Nanosphere Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanosphere and related companies with MarketBeat.com's FREE daily email newsletter.